Mayank Mamtani
Stock Analyst at B.Riley Financial
Total Price Targets
7
Stocks Covered
7
Sectors
Healthcare
Most Recent
Mar 4, 2026
Notable Calls (Last 12 Months)
Stocks Covered by Mayank Mamtani
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| TBPH | Theravance Biopharma Inc | $14.00 | $17.03 | -17.8% | 1 | Mar 4, 2026 |
| NVAX | Novavax, Inc. | $22.00 | $9.32 | +135.9% | 1 | Nov 18, 2024 |
| TRVI | Trevi Therapeutics, Inc. | $6.00 | $15.16 | -60.4% | 1 | Oct 4, 2024 |
| MGNX | MacroGenics, Inc. | $5.00 | $4.01 | +24.5% | 1 | Jul 31, 2024 |
| CYTK | Cytokinetics, Incorporated | $92.00 | $70.18 | +31.1% | 1 | Jun 4, 2024 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $270.00 | $528.08 | -48.9% | 1 | Mar 15, 2024 |
| TGTX | TG Therapeutics, Inc. | $11.50 | $55.78 | -79.4% | 1 | Apr 18, 2022 |
Recent Activity
- Mar 4, 2026— Set$14.00price target onTBPH(Theravance Biopharma Inc)
- Nov 18, 2024— Set$22.00price target onNVAX(Novavax, Inc.)
- Oct 4, 2024— Set$6.00price target onTRVI(Trevi Therapeutics, Inc.)
- Jul 31, 2024— Set$5.00price target onMGNX(MacroGenics, Inc.)
- Jun 4, 2024— Set$92.00price target onCYTK(Cytokinetics, Incorporated)
- Mar 15, 2024— Set$270.00price target onMDGL(Madrigal Pharmaceuticals, Inc.)
- Apr 18, 2022— Set$11.50price target onTGTX(TG Therapeutics, Inc.)
Frequently Asked Questions
Who is Mayank Mamtani?
Mayank Mamtani is a stock analyst at B.Riley Financial covering 7 stocks primarily in Healthcare. They have issued 7 price targets since Apr 18, 2022.
What stocks does Mayank Mamtani cover?
Mayank Mamtani currently covers 7 stocks, including TBPH, NVAX, TRVI, MGNX, CYTK.
What is Mayank Mamtani's latest price target?
Mayank Mamtani's most recent price target was $14.00 on TBPH (Theravance Biopharma Inc), set on Mar 4, 2026.
What is Mayank Mamtani's highest price target?
Mayank Mamtani's highest issued price target is $270.00 on MDGL, set on Mar 15, 2024.
More Analysts at B.Riley Financial
Coverage based on publicly published price targets. Not investment advice.